Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 57%
Buy 36%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. is demonstrating significant progress in its clinical pipeline, particularly with product candidates RLY-4008 and RLY-2608, which have shown promising efficacy metrics, including an overall response rate (ORR) of 67% among patients with kinase mutations. The company’s innovative Dynamo platform enhances its capability to tackle difficult drug-protein targets, positioning it favorably within the precision oncology space. Furthermore, with anticipated cash reserves of $781 million to fully fund ongoing trials, Relay Therapeutics is well-positioned to advance its promising therapies while potentially increasing investor confidence in its long-term outlook.

Bears say

The financial outlook for Relay Therapeutics Inc is negatively impacted by a projected full-year 2025 net loss of $2.15 per share, indicating continued financial strain. Key risks include potential negative clinical data, setbacks in development timelines, and the possibility of failures in obtaining regulatory approvals, all of which could hinder the progress of their pipeline candidates. Additionally, the competitive landscape presents challenges, particularly concerning therapies that may exhibit safety limitations leading to reduced commercial success, along with the risk of dilution in the medium to long term.

RLAY has been analyzed by 14 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 36% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 14 analysts, RLAY has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.